<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - METOCLOPRAMIDE HYDROCHLORIDE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>METOCLOPRAMIDE HYDROCHLORIDE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#importantSafetyInformation" data-toggle="tab">Important safety information</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Symptomatic treatment of nausea and vomiting including that associated with acute migraine</span>,
                <span class="indication">Delayed (but not acute) chemotherapy-induced nausea and vomiting</span>,
                <span class="indication">Radiotherapy-induced nausea and vomiting</span>,
                <span class="indication">Prevention of postoperative nausea and vomiting</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth or by intramuscular injection or by slow intravenous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults (body-weight up to 60 kg)</strong><br/>
                Up to 500 micrograms/kg daily in 3 divided doses, when administered by slow intravenous injection, to be given over at least 3 minutes.</li>
              <li class="dose adult"><strong>For adults (body-weight 60 kg and above)</strong><br/>
                10 mg up to 3 times a day, when administered by slow intravenous injection, to be given over at least 3 minutes.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Hiccup in palliative care</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth or by intramuscular injection or by subcutaneous injection</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                10 mg every 6&#8211;8 hours.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Nausea and vomiting in palliative care</span>,
            </h4>
            <p class="specificity"><span class="route">By subcutaneous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                10 mg 3 times a day.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                30&#8211;100 mg/24 hours.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Not known to be harmful.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="doseAdjustments">
              <p>Reduce dose.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <p>Avoid or use small dose in severe impairment; increased risk of extrapyramidal reactions.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

          <ul>
            <li>3&#8211;4 days after gastrointestinal surgery</li>
            <li>gastro-intestinal haemorrhage</li>
            <li>gastro-intestinal obstruction</li>
            <li>gastro-intestinal perforation</li>
            <li>phaeochromocytoma</li>
          </ul>
      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Extrapyramidal effects (especially in children and young adults (15&#8211;19 years old)), galactorrhoea, gynaecomastia, hyperprolactinaemia, menstrual changes,
              </p>
              <p>
                <strong>veryRare:</strong> Depression, methaemoglobinaemia (more severe in G6PD deficiency), neuroleptic malignant syndrome,
              </p>
              <p>
                <strong>notKnown:</strong> Anxiety, confusion, diarrhoea, dizziness, drowsiness, dyspnoea, hypotension, oedema, pruritus, rash, restlessness, tardive dyskinesia on prolonged administration, tremor, urticaria, visual disturbances,
              </p>
        
          <h3>Specific side effects</h3>
              <p>
                <strong>veryRare:</strong> cardiac conduction abnormalities,
              </p>
        
            <section class="advice">
              <p>Metoclopramide can induce acute dystonic reactions involving facial and skeletal muscle spasms and oculogyric crises. These dystonic effects are more common in the young (especially girls and young women) and the very old; they usually occur shortly after starting treatment with metoclopramide and subside within 24 hours of stopping it. Injection of an antiparkinsonian drug such as procyclidine will abort dystonic attacks.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <p>Oral liquid preparation to be given via a graduated oral dosing syringe.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
              <p>Counselling on use of pipette advised with oral solution.</p>
            </section>
      </section>


      <section class="tab-pane" id="importantSafetyInformation">
        <h2>Important safety information</h2>

            <section class="importantSafetyInformation">
                <h3>MHRA/CHM advice&amp;#8212;Metoclopramide: risk of neurological adverse effects&amp;#8212;restricted dose and duration of use (August 2013)</h3>
              <p>The benefits and risks of metoclopramide have been reviewed by the European Medicines Agency&#8217;s Committee on Medicinal Products for Human Use, which concluded that the risk of neurological effects such as extrapyramidal disorders and tardive dyskinesia outweigh the benefits in long-term or high-dose treatment. To help minimise the risk of potentially serious neurological adverse effects, the following restrictions to indications, dose, and duration of use have been made:</p><ul>
            <li>In adults over 18 years, metoclopramide should only be used for prevention of postoperative nausea and vomiting, radiotherapy-induced nausea and vomiting, delayed (but not acute) chemotherapy-induced nausea and vomiting, and symptomatic treatment of nausea and vomiting, including that associated with acute migraine (where it may also be used to improve absorption of oral analgesics);</li>
            <li>Metoclopramide should only be prescribed for short-term use (up to 5 days);</li>
            <li>Usual dose is 10&#8239;mg, repeated up to 3 times daily; max. daily dose is 500&#8239;micrograms/kg;</li>
            <li>Intravenous doses should be administered as a slow bolus over at least 3 minutes;</li>
            <li>Oral liquid formulations should be given via an appropriately designed, graduated oral syringe to ensure dose accuracy.</li>
            </ul><p>This advice does not apply to unlicensed uses of metoclopramide (e.g. palliative care).</p>
            </section>
      </section>

      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Asthma
          </li>
          <li>
            atopic allergy
          </li>
          <li>
            bradycardia
          </li>
          <li>
            cardiac conduction disturbances
          </li>
          <li>
            children
          </li>
          <li>
            elderly
          </li>
          <li>
            epilepsy
          </li>
          <li>
            may mask underlying disorders such as cerebral irritation
          </li>
          <li>
            Parkinson's disease
          </li>
          <li>
            uncorrected electrolyte imbalance
          </li>
          <li>
            young adults (15&#8211;19 years old)
          </li>
        </ul>
      </section>













      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of METOCLOPRAMIDE HYDROCHLORIDE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            oral solution,

            <div id="PHP77589"><a href="../medicinalForm/PHP77589.html" data-target="#PHP77589" data-action="load">Tablet</a></div>
            <div id="PHP77606"><a href="../medicinalForm/PHP77606.html" data-target="#PHP77606" data-action="load">Oral solution</a></div>
            <div id="PHP77602"><a href="../medicinalForm/PHP77602.html" data-target="#PHP77602" data-action="load">Solution for injection</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
